

Cora N Sternberg

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9066536/cora-n-sternberg-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

330
papers

33,400
citations

73
h-index

181
g-index

356
ext. papers

40,259
ext. citations

8.5
avg, IF

6.61
L-index

#	Paper	IF	Citations
330	Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.. <i>British Journal of Cancer</i> , 2022 ,	8.7	1
329	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. <i>European Journal of Cancer</i> , 2022 , 163, 55-65	7.5	0
328	Clinical Trials Corner Issue 8(1). <i>Bladder Cancer</i> , 2022 , 1-3	1	
327	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , 2022 , 18, 35-45	3.6	0
326	Serial ctDNA evaluation to predict clinical progression in patients with advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 532-532	2.2	
325	Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 13-13	2.2	0
324	Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 77-77	2.2	1
323	TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS581-TPS581	2.2	0
322	PATRIOT II: An ambispective, observational, multicenter, 2-cohort study of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS578-TPS578	2.2	
321	Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 512-512	2.2	
320	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. <i>European Urology</i> , 2022 ,	10.2	2
319	Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 37-37	2.2	
318	Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naïve metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS216-TPS216 ²	2.2	1 ¹
317	TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 434-434	2.2	1
316	Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.. <i>New England Journal of Medicine</i> , 2022 ,	59.2	30
315	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.. <i>Nature Communications</i> , 2022 , 13, 1878	17.4	1
314	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials.. <i>Clinical Cancer Research</i> , 2022 ,	12.9	2

313	Clinical Trials Corner Issue 8(2). <i>Bladder Cancer</i> , 2022 , 1-3	1	
312	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. <i>Nature Medicine</i> , 2021 ,	50.5	6
311	Clinical Trials Corner Issue 7(4). <i>Bladder Cancer</i> , 2021 , 1-4	1	
310	Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. <i>European Urology</i> , 2021 , 81, 50-50	10.2	4
309	Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. <i>European Journal of Cancer</i> , 2021 , 159, 237-246	7.5	2
308	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. <i>European Urology Focus</i> , 2021 , 7, 1084-1091	5.1	0
307	Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>European Urology</i> , 2021 , 79, 334-338	10.2	11
306	Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease. <i>Japanese Journal of Clinical Oncology</i> , 2021 , 51, 1287-1297	2.8	1
305	Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians. <i>European Urology</i> , 2021 , 79, 519-529	10.2	8
304	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 525-537	21.7	73
303	Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS5095-TPS5095	2.2	
302	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4527-4527	2.2	3
301	Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5040-5040	2.2	
300	Clinical Trials Corner Issue 7(2). <i>Bladder Cancer</i> , 2021 , 7, 257-260	1	
299	Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5055-5055	2.2	
298	Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5015-5015	2.2	4
297	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1553-1562	2.2	13
296	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1563-1574	2.2	19

295	Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. <i>Cancer Treatment Reviews</i> , 2021 , 97, 102187	14.4	9
294	Differential Activity of PARP Inhibitors in - Versus -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	2
293	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2021 , 398, 131-142	4.0	27
292	Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. <i>Translational Oncology</i> , 2021 , 14, 100944	4.9	2
291	A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, TPS188-TPS188		
290	PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 13-13	2.2	7
289	Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 140-140	2.2	
288	Efficacy of platinum re-challenge in metastatic urothelial carcinoma (mUC): A retrospective comparison of chemotherapy regimens.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 459-459	2.2	
287	PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 84-84	2.2	0
286	Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 438-438	2.2	5
285	An open-label, multicenter, phase IIIb study of patients with urinary tract carcinoma (UTC) (STRONG): Final analysis for fixed-dose durvalumab monotherapy (module A).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 429-429	2.2	
284	Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 120-120	2.2	1
283	Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 101-101	2.2	1
282	Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 94-94	2.2	0
281	Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 158-158	2.2	
280	Clinical Trials Corner Issue 7(1). <i>Bladder Cancer</i> , 2021 , 7, 103-106	1	
279	Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. <i>Oncologist</i> , 2021 , 26, 1026-1034	5.7	1
278	Clinical Trials Corner Issue 7(3). <i>Bladder Cancer</i> , 2021 , 7, 381-384	1	

277	Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. <i>Journal of Urology</i> , 2021 , 206, 240-251	2.5	1
276	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2474-2485	2.2	57
275	Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. <i>Oncologist</i> , 2021 , 26, e1971-e1981	5.7	1
274	Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. <i>European Urology</i> , 2021 , 80, 497-506 ^{10.2}		3
273	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. <i>Clinical Cancer Research</i> , 2021 ,	12.9	3
272	Clinical Trials Corner. <i>Bladder Cancer</i> , 2020 , 6, 93-95	1	
271	Clinical Trials Corner. <i>Bladder Cancer</i> , 2020 , 6, 219-221	1	
270	Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 680-688	6.2	9
269	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 2197-2206	59.2	114
268	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. <i>Cancer Treatment Reviews</i> , 2020 , 88, 102057	14.4	13
267	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547	10.2	155
266	Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5515-5515	2.2	10
265	Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5559-5559	2.2	1
264	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, LBA1-LBA1	2.2	44
263	Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 16-16	2.2	3
262	Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 182-182	2.2	6
261	Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 32-32	2.2	1
260	FORT-1: Phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 489-489	2.2	15

259	FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastatic urothelial cancer (UC) and FGFR genetic aberrations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS590-TPS590	2.2	1
258	Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 50-50	2.2	
257	Serial circulating tumor DNA (ctDNA) measurement to predict progression in patients (pts) with advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 558-558	2.2	
256	Clinical Trials Corner Issue 6(3). <i>Bladder Cancer</i> , 2020 , 6, 395-398	1	
255	Cell cycle inhibition to target the Evolution of urothelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS606-TPS606	2.2	0
254	CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5569-5569	2.2	0
253	Cell cycle inhibition to target the Evolution of urothelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5096-TPS5096	2.2	
252	Clinical Trials Corner Issue 6(4). <i>Bladder Cancer</i> , 2020 , 6, 553-556	1	
251	Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 284-294	3.3	37
250	Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020 , 4, 29-39	0.6	1
249	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2020 , 21, 105-120	21.7	35
248	Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. <i>JAMA Oncology</i> , 2020 , 6, 217-225	13.4	10
247	Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. <i>European Journal of Cancer</i> , 2020 , 138, 202-211	7.5	10
246	Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. <i>European Urology</i> , 2020 , 78, 847-853	10.2	2
245	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 934.e1-934.e9	2.8	0
244	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020 , 1, 1041-1053	15.4	18
243	Common germline-somatic variant interactions in advanced urothelial cancer. <i>Nature Communications</i> , 2020 , 11, 6195	17.4	6
242	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a or Gene Alteration. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3763-3772	2.2	164

241	Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020 , 5,	6	12
240	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020 , 383, 1218-1230	59.2	294
239	Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. <i>Lancet Oncology, The</i> , 2020 , 21, 1513-1525	21.7	13
238	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. <i>European Urology Oncology</i> , 2020 , 3, 671-679	6.7	7
237	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. <i>European Urology Oncology</i> , 2020 , 3, 94-101	6.7	17
236	Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. <i>European Urology Oncology</i> , 2020 , 3, 176-182	6.7	10
235	-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. <i>JCO Precision Oncology</i> , 2020 , 4, 370-381	3.6	66
234	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 2506-2518	59.2	219
233	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019 , 15, 929-941	3.6	23
232	Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study. <i>JAMA Oncology</i> , 2019 , 5, 1159-1167	13.4	19
231	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. <i>European Urology</i> , 2019 , 76, 73-81	10.2	74
230	Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer. <i>Future Oncology</i> , 2019 , 15, 1437-1457	3.6	13
229	Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. <i>European Urology Oncology</i> , 2019 , 2, 677-684	6.7	10
228	Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. <i>Clinical Cancer Research</i> , 2019 , 25, 3839-3846	12.9	90
227	Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program 2019 , 7, 99		71
226	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 556-569	21.7	56
225	Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. <i>BJU International</i> , 2019 , 123, 98-105	5.6	48
224	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. <i>European Urology</i> , 2019 , 76, 425-429	10.2	10

223	Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4519-4519	2.2	1
222	Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 253-253	2.2	3
221	Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 256-256	2.2	8
220	TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS495-TPS495	2.2	3
219	A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 185-185	2.2	0
218	The clinical impact of bone scan (BS) flare with enzalutamide (ENZA) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 183-183	2.2	
217	External validation of a prognostic model for overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5022-5022	2.2	
216	Multi-gene hereditary cancer testing, family history and prognosis in men with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5073-5073	2.2	
215	Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16077-e16077	2.2	0
214	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16017-e16017	2.2	
213	Concurrent or layered treatment with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5026-5026	2.2	
212	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 425-435.e4	3.3	9
211	Clinical Trials Corner. <i>Bladder Cancer</i> , 2019 , 5, 83-84	1	
210	Clinical Trials Corner. <i>Bladder Cancer</i> , 2019 , 5, 185-187	1	
209	Clinical Trials Corner. <i>Bladder Cancer</i> , 2019 , 5, 309-311	1	
208	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. <i>European Urology Oncology</i> , 2019 , 2, 248-256	6.7	9
207	Somatic and germline sequencing in genitourinary oncology: genetics for the clinician. <i>Current Opinion in Urology</i> , 2019 , 29, 315-318	2.8	1
206	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. <i>Oncologist</i> , 2019 , 24, 1348-1355	5.7	7

205	Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	7
204	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 95-105	4	12
203	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. <i>European Urology Focus</i> , 2019 , 5, 242-249	5.1	6
202	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. <i>European Urology</i> , 2019 , 75, 88-99	10.2	216
201	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 694-701	13.4	32
200	Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018 , 24, 3005-3013	12.9	37
199	The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer. <i>Cancer Treatment Reviews</i> , 2018 , 68, 25-37	14.4	27
198	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018 , 73, 178-211	10.2	313
197	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist® Perspective from a Multicentre Study. <i>European Urology Focus</i> , 2018 , 4, 937-945	5.1	6
196	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e945-e951	3.3	22
195	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1579-1587	2.2	68
194	Clinical Trials Corner. <i>Bladder Cancer</i> , 2018 , 4, 447-449	1	
193	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. <i>Frontiers in Oncology</i> , 2018 , 8, 463	5.3	17
192	Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 944-951	13.4	50
191	Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. <i>European Urology</i> , 2018 , 74, 611-620	10.2	49
190	Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 2465-2474	59.2	525
189	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017 , 376, 1015-1026	59.2	1788
188	Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. <i>Oncologist</i> , 2017 , 22, 667-679	5.7	50

187	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>European Urology</i> , 2017 , 71, 281-289	10.2	41
186	Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3916-3923	22.2	204
185	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 2266-2277	40	121
184	Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017 , 71, 168-171	10.2	38
183	Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. <i>European Urology</i> , 2017 , 71, 151-154	10.2	202
182	Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study. <i>JAMA Oncology</i> , 2017 , 3, 68-75	13.4	26
181	Clinical Trials Corner. <i>Bladder Cancer</i> , 2016 , 2, 469-471	1	
180	Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 106, 14-24	7	7
179	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3005-13	2.2	163
178	Clonal evolution of chemotherapy-resistant urothelial carcinoma. <i>Nature Genetics</i> , 2016 , 48, 1490-1499	36.3	161
177	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 917-927	21.7	580
176	Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial. <i>European Urology</i> , 2016 , 69, 1155-6	10.2	2
175	The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016 , 70, 675-683	10.2	57
174	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1402-18	2.2	666
173	A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up. <i>Annals of Nuclear Medicine</i> , 2016 , 30, 163-8	2.5	27
172	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 545-557	40	630
171	The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016 , 2, 480-487	5.1	9
170	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016 , 1, e000097	6	59

169	Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. <i>Annals of Surgical Oncology</i> , 2015 , 22, 2094-100	3.1	48
168	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 133-43	7	19
167	Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 509-21	21.7	138
166	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015 , 10, 517-22	5	32
165	Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 417-25	21.7	116
164	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. <i>Oncologist</i> , 2015 , 20, 1028-35	5.7	22
163	A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. <i>European Urology</i> , 2015 , 67, 100-110	10.2	106
162	Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 3325-39	4.4	33
161	Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 76-86	21.7	237
160	Enzalutamide in European and North American men participating in the AFFIRM trial. <i>BJU International</i> , 2015 , 115, 41-9	5.6	11
159	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology, The</i> , 2015 , 16, 152-60	21.7	856
158	Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. <i>Current Drug Targets</i> , 2015 , 16, 164-70	3	36
157	Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2015 , 4, 355-64	2.3	13
156	Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. <i>European Urology</i> , 2014 , 66, 120-37	10.2	190
155	Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1412-8	2.2	314
154	Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1147-56	21.7	154
153	Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1263-8	21.7	40
152	Enzalutamide in metastatic prostate cancer before chemotherapy. <i>New England Journal of Medicine</i> , 2014 , 371, 424-33	59.2	1892

151	Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 130-7	3.3	26
150	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 286-96	21.7	215
149	Pharmacotherapy options for advanced renal cell carcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 643-652	1.1	
148	A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. <i>BJU International</i> , 2014 , 113, E137-43	5.6	28
147	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4172-3	2.2	
146	Reply to S. Barni et Al and M. Sun et Al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3783-4	2.2	0
145	Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 262-9	3.3	8
144	Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor- κ B ligand inhibitors in patients with advanced prostate cancer. <i>European Urology</i> , 2014 , 65, 278-86	10.2	34
143	Reducing the burden of bone metastases: current concepts and treatment options. <i>Supportive Care in Cancer</i> , 2013 , 21, 1773-83	3.9	22
142	Pazopanib versus sunitinib in metastatic renal-cell carcinoma. <i>New England Journal of Medicine</i> , 2013 , 369, 722-31	59.2	1332
141	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. <i>European Urology</i> , 2013 , 63, 58-66	10.2	133
140	Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. <i>BJU International</i> , 2013 , 111, 44-52	5.6	55
139	Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. <i>European Urology</i> , 2013 , 63, 717-23	10.2	88
138	Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3791-9	2.2	310
137	Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1729-37	9.7	113
136	Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials. <i>Cancer</i> , 2013 , 119, 3610-8	6.4	38
135	Contemporary role of androgen deprivation therapy for prostate cancer. <i>European Urology</i> , 2012 , 61, 11-25	10.2	159
134	Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?. <i>European Urology</i> , 2012 , 61, 307-16	10.2	43

133	Novel molecular targets for the therapy of castration-resistant prostate cancer. <i>European Urology</i> , 2012 , 61, 950-60	10.2	54
132	The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. <i>European Urology</i> , 2012 , 61, 1212-21	10.2	22
131	Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care. <i>BJU International</i> , 2012 , 110, 1289-300	5.6	10
130	Increased survival with enzalutamide in prostate cancer after chemotherapy. <i>New England Journal of Medicine</i> , 2012 , 367, 1187-97	59.2	3075
129	Clinical and pharmacokinetic evaluation of satraplatin. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 103-11	5.5	27
128	Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). <i>Lancet, The</i> , 2012 , 380, 2018-27	4.0	594
127	A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. <i>European Urology</i> , 2012 , 62, 523-33	10.2	162
126	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. <i>Lancet Oncology, The</i> , 2012 , 13, 827-37	21.7	212
125	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology, The</i> , 2012 , 13, 983-92	21.7	965
124	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. <i>Lancet Oncology, The</i> , 2012 , 13, 1210-7	21.7	225
123	Neoadjuvant chemotherapy for invasive bladder cancer. <i>Current Urology Reports</i> , 2012 , 13, 136-46	2.9	16
122	Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment. <i>BJU International</i> , 2012 , 109, 200-6	5.6	26
121	An open-label, dose-finding study of the combination of satraplatin and gemcitabine in patients with advanced solid tumors. <i>Frontiers in Oncology</i> , 2012 , 2, 175	5.3	1
120	Dose escalation and pharmacokinetics study of enzastaurin and sunitinib versus placebo and sunitinib in patients with metastatic renal cell carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012 , 35, 493-7	2.7	6
119	Metastatic bladder cancer: anything new?. <i>Current Opinion in Supportive and Palliative Care</i> , 2012 , 6, 304-9.6		7
118	Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. <i>Expert Opinion on Drug Safety</i> , 2012 , 11, 851-9	4.1	16
117	Targeted therapies for renal cell carcinoma: review of adverse event management strategies. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 93-113	9.7	168
116	Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA1-LBA1	2.2	44

115	Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. <i>Urology</i> , 2011 , 77, 1166-71	1.6	78
114	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. <i>Lancet Oncology, The</i> , 2011 , 12, 211-4	21.7	186
113	Contemporary management of metastatic castration-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2011 , 21, 241-7	2.8	7
112	Toxicities of targeted therapy and their management in kidney cancer. <i>European Urology</i> , 2011 , 59, 526-40.2	10.2	89
111	The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. <i>European Urology</i> , 2011 , 60, 270-8	10.2	39
110	New therapies for castration-resistant prostate cancer: efficacy and safety. <i>European Urology</i> , 2011 , 60, 279-90	10.2	111
109	Sequelae of treatment in long-term survivors of testis cancer. <i>European Urology</i> , 2011 , 60, 516-26	10.2	56
108	ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. <i>European Urology</i> , 2011 , 60, 684-90	10.2	100
107	Abiraterone and increased survival in metastatic prostate cancer. <i>New England Journal of Medicine</i> , 2011 , 364, 1995-2005	59.2	3019
106	Pazopanib: Clinical development of a potent anti-angiogenic drug. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 77, 163-71	7	111
105	Sequential use of targeted agents in the treatment of renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 77, 48-62	7	48
104	Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2432-8	2.2	349
103	Role of targeted therapy in the treatment of advanced prostate cancer. <i>BJU International</i> , 2010 , 105, 748-67	5.6	22
102	Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. <i>BJU International</i> , 2010 , 106, 462-9	5.6	145
101	The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. <i>International Journal of Urology</i> , 2010 , 17, 228-40	2.3	7
100	Is there a role for presurgical therapy for renal cell carcinoma?. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 807-12	3.5	1
99	Castration-resistant prostate cancer: current and emerging treatment strategies. <i>Drugs</i> , 2010 , 70, 983-1000	10.0	77
98	Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. <i>Lancet Oncology, The</i> , 2010 , 11, 861-70	21.7	105

97	External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. <i>Lancet Oncology, The</i> , 2010 , 11, 1066-73	21.7	646
96	Neoadjuvant systemic therapy for urological malignancies. <i>BJU International</i> , 2010 , 106, 6-22	5.6	21
95	Novel targeted therapy for advanced renal carcinoma: trials in progress. <i>Current Opinion in Urology</i> , 2010 , 20, 382-7	2.8	5
94	Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 73, 68-91	7	78
93	Pazopanib in renal cell carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2010 , 8, 232-3	0.6	10
92	Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 7421-8	12.9	192
91	Satraplatin for the therapy of castration-resistant prostate cancer. <i>Future Oncology</i> , 2009 , 5, 931-40	3.6	7
90	Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5431-8	2.2	268
89	Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. <i>European Urology</i> , 2009 , 55, 62-75	10.2	115
88	Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. <i>European Urology</i> , 2009 , 55, 348-58	10.2	67
87	Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. <i>European Urology</i> , 2009 , 56, 594-605	10.2	123
86	Metastatic renal cell carcinoma: recent advances in the targeted therapy era. <i>European Urology</i> , 2009 , 56, 959-71	10.2	47
85	Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. <i>Cancer</i> , 2009 , 115, 2652-9	6.4	64
84	Management of good risk germ-cell tumours. <i>BJU International</i> , 2009 , 104, 1387-91	5.6	4
83	Systemic therapy and novel agents for metastatic castration resistant prostate cancer. <i>Update on Cancer Therapeutics</i> , 2009 , 3, 133-145		2
82	Optimizing outcomes at every stage of bladder cancer: do we practice it?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 72-4	2.8	14
81	Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment. <i>European Urology Supplements</i> , 2009 , 8, 738-746	0.9	4
80	Advances in the Management of Metastatic Renal Cell Cancer. <i>European Urology Supplements</i> , 2009 , 8, 758-761	0.9	

79	Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum. <i>European Urology Supplements</i> , 2009 , 8, 733-737	0.9	1
78	Novel agents for muscle-invasive and advanced urothelial cancer. <i>BJU International</i> , 2008 , 101, 937-43	5.6	9
77	The future of prostate cancer. <i>BJU International</i> , 2008 , 101, 934-6	5.6	
76	Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. <i>BJU International</i> , 2008 , 102, 1607-9	5.6	21
75	Treatment of metastatic urothelial cancer: opportunities for drug discovery and development. <i>BJU International</i> , 2008 , 102, 1354-60	5.6	14
74	Bladder cancer today. <i>BJU International</i> , 2008 , 102, 1203	5.6	
73	Differences in depressive thoughts between major depressive disorder, IFN-alpha-induced depression, and depressive disorders among cancer patients. <i>Journal of Psychosomatic Research</i> , 2008 , 65, 153-6	4.1	13
72	Novel treatment options for refractory germ cell tumors. <i>Update on Cancer Therapeutics</i> , 2008 , 3, 89-96		
71	Development of novel agents and combinations for renal carcinoma. <i>Update on Cancer Therapeutics</i> , 2008 , 3, 97-103		
70	Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 253-61	5.9	68
69	Antiangiogenic therapy in renal cell carcinoma: a plethora of choices. <i>Nature Reviews Urology</i> , 2008 , 5, 422-3		2
68	A new era in prostate cancer therapy: new targets and novel therapeutics. <i>Targeted Oncology</i> , 2008 , 3, 31-39	5	
67	The medical management of prostate cancer: a multidisciplinary team approach. <i>BJU International</i> , 2007 , 99, 22-7	5.6	26
66	Signal-transduction inhibitors in renal cell carcinoma. <i>BJU International</i> , 2007 , 99, 1289-95	5.6	9
65	Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer. <i>BJU International</i> , 2007 , 100, 533-5	5.6	3
64	Current indications for chemotherapy in prostate cancer patients. <i>European Urology</i> , 2007 , 51, 17-26	10.2	54
63	Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation. <i>Seminars in Oncology</i> , 2007 , 34, 122-8	5.5	10
62	Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments. <i>Critical Reviews in Oncology/Hematology</i> , 2007 , 61, 176-85	7	35

61	Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 257-62	2.2	108
60	Molecular pathways and the hope of targeting angiogenesis. <i>Nature Reviews Urology</i> , 2007 , 4, 470-1		1
59	Introduction: A multidisciplinary approach to genitourinary malignancy: does this topic warrant further debate?. <i>Nature Reviews Urology</i> , 2007 , 4, S1-S2		
58	The evolving role of chemotherapy in advanced urothelial cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2007 , 1, 180-6	2.6	1
57	Adjuvant bicalutamide for early prostate cancer: an update. <i>Nature Reviews Urology</i> , 2006 , 3, 408-9		
56	New treatment approaches in metastatic renal cell carcinoma. <i>Current Opinion in Urology</i> , 2006 , 16, 337-41	4.8	16
55	Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme. <i>BJU International</i> , 2006 , 97, 435-8	5.6	11
54	Cancer and its Management. <i>BJU International</i> , 2006 , 97, 651-651	5.6	2
53	What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer?. <i>BJU International</i> , 2006 , 98, 487-9	5.6	11
52	Current therapies and advances in the treatment of pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 58, 231-41	7	76
51	State-of-the-art management of metastatic disease at initial presentation or recurrence. <i>World Journal of Urology</i> , 2006 , 24, 543-56	4	13
50	What's new in the treatment of metastatic kidney cancer?. <i>BJU International</i> , 2005 , 95, 1171-80	5.6	8
49	Satraplatin in the treatment of hormone-refractory prostate cancer. <i>BJU International</i> , 2005 , 96, 990-4	5.6	26
48	Chemotherapy for local treatment of bladder cancer. <i>Seminars in Radiation Oncology</i> , 2005 , 15, 60-5	5.5	9
47	Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?. <i>Critical Reviews in Oncology/Hematology</i> , 2005 , 55, 67-81	7	24
46	Adjuvant chemotherapy for bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2005 , 5, 987-92	3.5	2
45	Numeric definition of the clinical performance of the nested reverse transcription-PCR for detection of hematogenous epithelial cells and correction for specific mRNA of non-target cell origin as evaluated for prostate cancer cells. <i>Clinical Chemistry</i> , 2003 , 49, 1458-66	5.5	33
44	Metastatic Bladder Cancer: Role of Chemotherapy and New Agents. <i>EAU Update Series</i> , 2003 , 1, 108-117		5

43	Guidelines on bladder cancer. <i>European Urology</i> , 2002 , 41, 105-12	10.2	302
42	Localized and locally advanced bladder cancer. <i>Current Treatment Options in Oncology</i> , 2002 , 3, 413-28	5.4	4
41	New drugs and new approaches for the treatment of metastatic urothelial cancer. <i>World Journal of Urology</i> , 2002 , 20, 158-66	4	30
40	Bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 41, 89-106	7	24
39	Highlights of contemporary issues in the medical management of prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 43, 105-21	7	17
38	Overview of international collaborative group prostate cancer trials. <i>Critical Reviews in Oncology/Hematology</i> , 2002 , 43, 153-8	7	2
37	High-risk metastatic urothelial cancer: chances for cure?. <i>Current Opinion in Urology</i> , 2002 , 12, 441-8	2.8	19
36	Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience. <i>Urology</i> , 2002 , 59, 227-31	1.6	103
35	Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. <i>Lancet, The</i> , 2002 , 360, 103-6	40	1381
34	Neo-adjuvant chemotherapy in invasive bladder cancer. <i>World Journal of Urology</i> , 2001 , 19, 94-8	4	15
33	Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patients. <i>European Urology</i> , 2001 , 39, 430-7	10.2	6
32	Second-line treatment of advanced transitional cell carcinoma of the urothelial tract. <i>Current Opinion in Urology</i> , 2001 , 11, 523-9	2.8	11
31	Second-line chemotherapy in advanced bladder cancer. <i>Urologia Internationalis</i> , 2000 , 64, 61-9	1.9	6
30	A critical review of the management of bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1999 , 31, 193-207	7	6
29	Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. <i>European Urology</i> , 1999 , 35, 52-6	10.2	91
28	The management of stage I testis cancer. <i>Urologic Clinics of North America</i> , 1998 , 25, 435-49	2.9	37
27	Muscle-invasive transitional cell carcinoma of the bladder: strategies for bladder preservation. <i>Current Opinion in Urology</i> , 1998 , 8, 431-5	2.8	
26	Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. <i>New England Journal of Medicine</i> , 1997 , 337, 295-300	59.2	1249

25	Neoadjuvant and adjuvant chemotherapy in locally advanced bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1997 , 3, 133-40	2.8	1
24	Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) chemotherapy and bladder preservation for muscle-infiltrating transitional cell carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 1995 , 1, 127-33	2.8	11
23	Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer. <i>Radiotherapy and Oncology</i> , 1995 , 35, 123-8	5.3	7
22	Bladder preservation--a prospect for patients with urinary bladder cancer. <i>Acta Oncologica</i> , 1995 , 34, 589-97; discussion 588	3.2	4
21	Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladder. <i>Cancer</i> , 1993 , 72, 1975-82	6.4	50
20	Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. <i>Cancer</i> , 1991 , 67, 1525-31	6.4	118
19	Transurethral resection of the prostate and metastatic prostate cancer. <i>Cancer</i> , 1991 , 68, 1895-8	6.4	15
18	Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. <i>Cancer</i> , 1991 , 68, 2561-5	6.4	72
17	Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1990 , 8, 391-2	4.3	17
16	Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen. <i>British Journal of Urology</i> , 1989 , 64, 250-6		93
15	Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. <i>Cancer</i> , 1989 , 64, 2448-58	6.4	573
14	Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program. <i>European Journal of Cancer & Clinical Oncology</i> , 1989 , 25, 753-4		9
13	Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. <i>New England Journal of Medicine</i> , 1988 , 318, 1414-22	59.2	813
12	Etoposide (VP-16) in the treatment of advanced adenocarcinoma of the pancreas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1988 , 11, 172-3	2.7	7
11	Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1988 , 11, 174-6	2.7	3
10	Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. <i>Journal of Urology</i> , 1988 , 139, 475-7	2.5	41
9	Evaluation of new anticancer agents against human pancreatic carcinomas in nude mice. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1987 , 10, 219-21	2.7	13
8	Phase II trial of 10 deaza-aminopterin in patients with bladder cancer. <i>Investigational New Drugs</i> , 1986 , 4, 171-4	4.3	4

7	Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease. <i>Cancer Chemotherapy and Pharmacology</i> , 1986 , 18, 24-6	3.5	19
6	Phase I/II trial of intravesical methotrexate for superficial bladder tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1986 , 18, 265-9	3.5	3
5	Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. <i>Journal of Urology</i> , 1985 , 133, 403-7	2.5	512
4	Phase II trial of 1,2-diaminocyclohexane-(4-carboxyphthalato) platinum(II) (DACCP) in colorectal carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1984 , 7, 503-5	2.7	2
3	MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1984 , 7, 529-33	2.7	2
2	Phase II evaluation of m-AMSA (4P(9-acridinylamino)-methanesulfon-m-anisidide) in patients with adenocarcinoma of the pancreas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1983 , 6, 459-62	2.7	5
1	Fine flutterings of the aortic valve as demonstrated by aortic valve echocardiograms. <i>American Heart Journal</i> , 1978 , 95, 807-8	4.9	15